Open Access Repository

Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

McNeil, JJ, Woods, RL, Nelson, MR ORCID: 0000-0001-9941-7161, Murray, AM, Reid, CM, Kirpach, B, Storey, E, Shah, RC, Wolfe, RS, Tonkin, AM, Newman, AB, Williamson, JD, Lockery, JE, Margolis, KL, Ernst, ME, Abhayaratna, WP, Stocks, N, Fitzgerald, SM, Trevaks, RE, Orchard, SG, Beilin, LJ, Donnan, GA, Gibbs, P, Johnston, CI and Grimm, RH 2017 , 'Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study' , Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, vol. 72, no. 11 , pp. 1586-1593 , doi: 10.1093/gerona/glw342.

Full text not available from this repository.


Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

Item Type: Article
Authors/Creators:McNeil, JJ and Woods, RL and Nelson, MR and Murray, AM and Reid, CM and Kirpach, B and Storey, E and Shah, RC and Wolfe, RS and Tonkin, AM and Newman, AB and Williamson, JD and Lockery, JE and Margolis, KL and Ernst, ME and Abhayaratna, WP and Stocks, N and Fitzgerald, SM and Trevaks, RE and Orchard, SG and Beilin, LJ and Donnan, GA and Gibbs, P and Johnston, CI and Grimm, RH
Keywords: Clinical trial, dementia, disability, primary prevention
Journal or Publication Title: Journals of Gerontology. Series A: Biological Sciences and Medical Sciences
Publisher: Gerontological Society Amer
ISSN: 1079-5006
DOI / ID Number: 10.1093/gerona/glw342
Copyright Information:

Copyright The Author 2017

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page